Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to catch type 1 diabetes early in At-Risk kids

NCT ID NCT07038473

Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 20, 2026 · Updated 4 times

Summary

This study is screening children and adolescents aged 1.5 to 18 years who have a parent or sibling with type 1 diabetes. Researchers will collect blood samples to look for early signs of the disease, such as specific autoantibodies, before symptoms appear. The goal is to identify pre-symptomatic type 1 diabetes and improve monitoring and data collection in Gulf countries.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better early detection and monitoring of type 1 diabetes in at-risk children, potentially allowing for earlier intervention.
What could go wrong
This is an observational study, not a treatment trial. It may not directly change outcomes, and the results might not apply to all populations or regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 months to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children and adolescents, age 1.5 years to 18 years * First degree relatives of T1D probands * Parent or legal guardian signing an informed consent Exclusion Criteria: * Already developed clinical overt T1D * Known diabetes of any kind (type 1, type 2, Maturity Onset Diabetes of the Young - MODY) * Have a previous history of being treated with insulin The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    7 sites in 3 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Dasman Diabetes Institute - Site Number: 08

    RECRUITING

    Kuwait City, Al Asimah / Capital Governorate, Kuwait

  • Imam Abdulrahman Bin Faisal University - Site Number: 05

    RECRUITING

    Dammam, Eastern Province, Saudi Arabia

  • King Abdulaziz Medical City, National Guard Hospital, Jeddah - Site Number: 01

    RECRUITING

    Jeddah, Mecca Region, Saudi Arabia

  • King Fahd Medical City - Site Number: 03

    RECRUITING

    Riyadh, Saudi Arabia

  • King Faisal Specialist Hospital & Research Centre - Site Number: 02

    RECRUITING

    Riyadh, Saudi Arabia

  • Sheikh Khalifa Medical City - Site Number: 07

    RECRUITING

    Abu Dhabi, United Arab Emirates

  • Sheikh Shakhbout Medical City - Site Number: 06

    RECRUITING

    Abu Dhabi, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.